Last reviewed · How we verify
L-ARG+GHRH — Competitive Intelligence Brief
phase 3
Growth hormone secretagogue / amino acid combination
GHRH receptor (GHRHR); nitric oxide pathway
Endocrinology / Metabolic disorders
Small molecule
Live · refreshed every 30 min
Target snapshot
L-ARG+GHRH (L-ARG+GHRH) — AEterna Zentaris. L-arginine combined with growth hormone-releasing hormone (GHRH) stimulates endogenous growth hormone secretion to promote anabolic effects and tissue repair.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| L-ARG+GHRH TARGET | L-ARG+GHRH | AEterna Zentaris | phase 3 | Growth hormone secretagogue / amino acid combination | GHRH receptor (GHRHR); nitric oxide pathway |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Growth hormone secretagogue / amino acid combination class)
- AEterna Zentaris · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- L-ARG+GHRH CI watch — RSS
- L-ARG+GHRH CI watch — Atom
- L-ARG+GHRH CI watch — JSON
- L-ARG+GHRH alone — RSS
- Whole Growth hormone secretagogue / amino acid combination class — RSS
Cite this brief
Drug Landscape (2026). L-ARG+GHRH — Competitive Intelligence Brief. https://druglandscape.com/ci/l-arg-ghrh. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab